IL172812A0 - Naphthylene derivatives as cytochrome p450 inhibitors - Google Patents

Naphthylene derivatives as cytochrome p450 inhibitors

Info

Publication number
IL172812A0
IL172812A0 IL172812A IL17281205A IL172812A0 IL 172812 A0 IL172812 A0 IL 172812A0 IL 172812 A IL172812 A IL 172812A IL 17281205 A IL17281205 A IL 17281205A IL 172812 A0 IL172812 A0 IL 172812A0
Authority
IL
Israel
Prior art keywords
cytochrome
inhibitors
naphthylene
derivatives
naphthylene derivatives
Prior art date
Application number
IL172812A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of IL172812A0 publication Critical patent/IL172812A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL172812A 2003-07-10 2005-12-26 Naphthylene derivatives as cytochrome p450 inhibitors IL172812A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48638203P 2003-07-10 2003-07-10
PCT/US2004/022282 WO2005007631A1 (fr) 2003-07-10 2004-07-12 Derives de naphtylene constituant des inhibiteurs du cytochrome p450

Publications (1)

Publication Number Publication Date
IL172812A0 true IL172812A0 (en) 2006-06-11

Family

ID=34079229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL172812A IL172812A0 (en) 2003-07-10 2005-12-26 Naphthylene derivatives as cytochrome p450 inhibitors

Country Status (15)

Country Link
EP (1) EP1654236A1 (fr)
JP (1) JP4832295B2 (fr)
KR (1) KR20060052799A (fr)
CN (1) CN1819996B (fr)
AU (1) AU2004257257B2 (fr)
BR (1) BRPI0412424A (fr)
CA (1) CA2532078A1 (fr)
IL (1) IL172812A0 (fr)
IS (1) IS8223A (fr)
MX (1) MXPA06000401A (fr)
NO (1) NO20060114L (fr)
RU (1) RU2363696C2 (fr)
SG (1) SG144941A1 (fr)
UA (1) UA87822C2 (fr)
WO (1) WO2005007631A1 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058301A1 (fr) * 2003-12-17 2005-06-30 Allergan, Inc. Procedes permettant de traiter des troubles sensibles au retinoide au moyen d'inhibiteurs selectifs de cyp26a et de cyp26b
US7662844B2 (en) 2004-07-12 2010-02-16 Osi Pharmaceuticals, Inc. Naphthylene derivatives as cytochrome P450 inhibitors
EP2576544A4 (fr) 2010-06-01 2013-09-11 Angion Biomedica Corp Inhibiteurs des cytochromes p450 et leurs utilisations
US10414760B2 (en) 2016-11-29 2019-09-17 Angion Biomedica Corp. Cytochrome P450 inhibitors and uses thereof
ES2703498T3 (es) * 2010-11-13 2019-03-11 Innocrin Pharmaceuticals Inc 1-(6,7-Bis(difluorometoxi)naftalen-2-il)-2-metil-1-(1H-1,2,3-triazol-4-il)propan-1-ol como inhibidor de CYP17 para el tratamiento de enfermedades dependientes de andrógenos como el cáncer de próstata
AU2011343966B2 (en) * 2010-12-13 2017-03-16 Innocrin Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN102586187A (zh) * 2012-02-23 2012-07-18 深圳市中美康士生物科技有限公司 一种中性粒细胞体外保存方法及培养基
WO2014015137A2 (fr) * 2012-07-18 2014-01-23 Angion Biomedica Corp. Compositions et méthodes de traitement de maladies dysprolifératives
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
CN104523967B (zh) * 2014-12-12 2017-08-01 扬子江药业集团北京海燕药业有限公司 一种柏艾胶囊作为cyp酶抑制剂的应用
WO2016109492A1 (fr) 2014-12-31 2016-07-07 Angion Biomedica Corp Méthodes et agents pour traiter une maladie
GB201602572D0 (en) * 2016-02-12 2016-03-30 Eriksson Leif And Strid Ake And Sirsjö Allan New compound and uses
WO2018065288A1 (fr) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft Dérivés de 2-[2-phényl-1-(sulfonylméthyl)vinyl]-imidazo[4,5-b]pyridine et composés apparentés utilisés comme pesticides en protection des plantes
US11083199B2 (en) 2017-01-10 2021-08-10 Bayer Aktiengesellschaft Heterocycle derivatives as pesticides
WO2018130437A1 (fr) 2017-01-10 2018-07-19 Bayer Aktiengesellschaft Dérivés hétérocycliques utilisés comme pesticides

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL291944A (fr) * 1960-05-04
NL131915C (fr) * 1966-07-27
DE3508903A1 (de) * 1985-03-13 1986-09-18 Hoechst Ag, 6230 Frankfurt Neue 3-pyridylmethylnaphtylderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE3628545A1 (de) * 1985-09-23 1987-04-23 Hoechst Ag Arylmethylazole und deren salze, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
WO1994008973A1 (fr) * 1992-10-21 1994-04-28 Sankyo Company, Limited Compose de type azole
EP1073640B1 (fr) * 1998-04-23 2005-04-13 Takeda Pharmaceutical Company Limited Derives de naphtalene, leur production et utilisation
JP4546589B2 (ja) * 1998-04-23 2010-09-15 武田薬品工業株式会社 ナフタレン誘導体
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
JP4520012B2 (ja) * 1999-10-22 2010-08-04 武田薬品工業株式会社 １−置換−１−（１ｈ−イミダゾール−４−イル）メタノール類
PE20010781A1 (es) * 1999-10-22 2001-08-08 Takeda Chemical Industries Ltd Compuestos 1-(1h-imidazol-4-il)-1-(naftil-2-sustituido)etanol, su produccion y utilizacion

Also Published As

Publication number Publication date
CN1819996B (zh) 2010-10-27
AU2004257257A1 (en) 2005-01-27
IS8223A (is) 2006-01-10
MXPA06000401A (es) 2006-03-17
KR20060052799A (ko) 2006-05-19
NO20060114L (no) 2006-02-09
RU2006103996A (ru) 2006-07-10
AU2004257257B2 (en) 2011-05-12
CN1819996A (zh) 2006-08-16
JP4832295B2 (ja) 2011-12-07
EP1654236A1 (fr) 2006-05-10
CA2532078A1 (fr) 2005-01-27
BRPI0412424A (pt) 2006-09-05
RU2363696C2 (ru) 2009-08-10
UA87822C2 (ru) 2009-08-25
JP2007523866A (ja) 2007-08-23
WO2005007631A1 (fr) 2005-01-27
SG144941A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
IL172812A0 (en) Naphthylene derivatives as cytochrome p450 inhibitors
GB2413769B (en) Ureteric stents
HK1102328A1 (en) Macrocyclic beta-secretase inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
HK1107348A1 (en) Indozolone derivatives as 11b-hsd1 inhibitors
HK1104543A1 (en) Thiazole derivative
IL178313A0 (en) Morpholine compounds
IL180242A0 (en) Piperidine derivatives as renin inhibitors
AP2009004763A0 (en) Pyrazole derivatives as cytochrome P450 inhibitors
EP1810965A4 (fr) Derives d'hydrazide
AP2074A (en) New 4-benzylidene-piperidin derivatives
EP1778855A4 (fr) Enzymes carotenoide hydroxylase
EP1801108A4 (fr) Derive de morpholine
HK1101638A1 (en) New pyridothienopyrimidine derivatives
HK1100002A1 (en) 4-phenyl-pyrimidine-2-carbonitrile derivatives
IL183141A0 (en) New pyridothienopyrimidine derivatives
GB0414272D0 (en) OsK1 derivatives
GB2411300B (en) Earth connections for workpieces
GB0407767D0 (en) Ureteric stent
GB0421919D0 (en) Cytochrome P450 prodrug target
GB0319035D0 (en) Cytochrome p450 protein
AU2003255732A8 (en) Cytochrome p450s
WO2004078905A8 (fr) Agents de phytoremediation
GB0405905D0 (en) Azaquinazoline derivatives